drugset / Trial / NCT05303701
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
Timeline
- Start
- 2027-07
- Primary completion
- 2028-01
- Completion
- 2031-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TERTOMOTIDE | Vaccine | 1.12 mg | Subcutaneous |